Karbicombi (Hydrochlorothiazide, Candesartan Cilexetil)

Hydrochlorothiazide reduces blood volume by blocking sodium‑chloride reabsorption in the distal tubule, promoting diuresis. Candesartan cilexetil blocks AT₁ receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Together they decrease peripheral resistance and plasma volume, producing a combined reduction in arterial pressure.

The dose of Karbicombi is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, electrolyte status, and response to therapy. No fixed regimen is provided here; the prescriber will select the appropriate strength and dosing schedule according to clinical guidelines.

Safety data for Karbicombi in pregnancy and lactation are limited. Candesartan is generally contraindicated in the second and third trimesters, and thiazide diuretics are used with caution. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare professional.

To request Karbicombi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Karbicombi offers a fixed‑dose combination of a thiazide diuretic and an ARB, which can simplify regimens and improve adherence compared with taking separate agents. Compared with ACE inhibitors, it avoids cough and angioedema risk, while providing similar blood‑pressure control. It may be preferred when a patient needs both diuretic and renin‑angiotensin blockade.

Karbicombi tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in areas of high humidity or near heat sources, and keep out of reach of children.

Karbicombi is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious adverse events include severe dehydration, hyperkalemia, angioedema, acute kidney injury, and profound hypotension. These conditions require immediate medical attention. Regular monitoring of electrolytes, renal function, and blood pressure helps mitigate these risks.

Karbicombi should be avoided in patients with severe renal impairment, known hypersensitivity to either component, or those taking contraindicated medications such as aliskiren in combination with an ARB. Caution is also advised for individuals with a history of angioedema, hyperkalemia, or significant electrolyte disturbances.